Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Lung Cancer

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cllc.2014.09.011PMID 25458559
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmaceutical approval update.

  2014cited by this paper
• Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

  2014cited by this paper
• ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?

  2014cited by this paper
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014influential reference
• Overcoming drug resistance in ALK-rearranged lung cancer.

  2014cited by this paper
• ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?

  2014influential reference
• ALK inhibitors in the treatment of advanced NSCLC.

  2014cited by this paper
• Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.

  2014cited by this paper
• Ceritinib gains FDA approval for lung cancer.

  2014cited by this paper
• Second-generation ALK inhibitors: filling the non "MET" gap.

  2014cited by this paper
• Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?

  2014influential reference
• Immunotherapy in the treatment of non-small cell lung cancer.

  2014cited by this paper
• Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

  2014influential reference
• Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

  2014cited by this paper
• First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014influential reference
• NICE: moving onward.

  2013cited by this paper
• Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.

  2013cited by this paper
• Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

  2013influential reference
• Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer

  2013influential reference
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013influential reference
• LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.

  2013cited by this paper
• Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2

  2013cited by this paper
• ALK in lung cancer: past, present, and future.

  2013influential reference
• Crizotinib for the treatment of non-small-cell lung cancer.

  2013cited by this paper
• Cancer drugs in the United States: Justum Pretium--the just price.

  2013cited by this paper
• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

  2012cited by this paper
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

  2012cited by this paper
• Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

  2011cited by this paper
• Pharmaceutical approval update.

  2011cited by this paper
• Predictors of competing mortality in advanced head and neck cancer.

  2010cited by this paper
• PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).

  2010cited by this paper
• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

  2007influential reference
• Cancer statistics

  1989cited by this paper

• Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance

  2025cites this paper
• Novel ALK inhibitors containing DAAP fragments: Rational drug design and anti-tumor activity research.

  2025cites this paper
• Recent Advances in Synthetic Isoquinoline-Based Derivatives in Drug Design

  2025cites this paper
• Mechanistic insights into novel cyano-pyrimidine pendant chalcone derivatives as LSD1 inhibitors by docking, ADMET, MM/GBSA, and molecular dynamics simulation

  2025cites this paper
• Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma

  2022cites this paper
• Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections

  2021influential citation
• Development of multivariable risk signature based on four immune-related RNA-binding proteins to predict survival and immune status in lung adenocarcinoma

  2021cites this paper
• Dynamic protein quantitation (DyProQ) of procollagen-I by CRISPR-Cas9 NanoLuciferase tagging

  2020cites this paper
• Insight into the binding behavior of ceritinib on human α-1 acid glycoprotein: Multi-spectroscopic and molecular modeling approaches.

  2020cites this paper
• Biomarkers for CNS metastasis in Non-Small Cell Lung Cancer (NSCLC)

  2020cites this paper
• Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.

  2020cites this paper
• Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)

  2020cites this paper
• Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China

  2019cites this paper
• Drug discovery targeting anaplastic lymphoma kinase (ALK).

  2019cites this paper
• VEGF and FGF-2: Promising targets for the treatment of respiratory disorders.

  2019cites this paper
• Advances in studies of tyrosine kinase inhibitors and their acquired resistance

  2018cites this paper
• Inhibition of Collagen Related Peptide Induced Platelet Activation and Apoptosis by Ceritinib

  2018cites this paper
• Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

  2017cites this paper
• Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

  2017cites this paper
• Kinase Inhibitors in Multitargeted Cancer Therapy.

  2017cites this paper
• Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting

  2017cites this paper
• Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

  2017cites this paper
• First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.

  2017cites this paper
• Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.

  2017cites this paper
• ALK is a therapeutic target for lethal sepsis

  2017cites this paper
• Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer

  2016cites this paper
• Stimulation of Suicidal Erythrocyte Death by Ceritinib-Treatment of Human Erythrocytes

  2016cites this paper
• Nemalobuněčný karcinom plic – od imunobio logie k imunoterapii Non-Small Cell Lung Cancer – from Immunobio logy to Immunotherapy

  2016cites this paper
• Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis.

  2016cites this paper
• Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives

  2016cites this paper
• Synthetic approaches to the 2014 new drugs.

  2016cites this paper
• Alectinib for ALK-positive non-small-cell lung cancer

  2016cites this paper
• Crizotinib and Ceritinib Induce Apoptosis and Necrosis in Primary Rat Hepatocytes with Distinct Capacity

  2016cites this paper
• Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

  2015cites this paper
• Somatic DNA mutation analysis in targeted therapy of solid tumours.

  2015cites this paper
• Anaplastic lymphoma kinase inhibitors

  2015cites this paper
• Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.

  2015cites this paper
• Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.

  2015cites this paper
• Optionen für die Behandlung von Hirnmetastasen

  2015cites this paper
• Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?

  2015cites this paper
• The future of targeted therapies for brain metastases.

  2015cites this paper